Amarin Corporation (AMRN) Price to Earnings Ratio

Corporate emblem and logo of Amarin Corp (AMRN)

Price action characterized by the -12.60 indicator demonstrates the position of Amarin Corporation plc (AMRN), which attracts leading cardiologists through prestigious projects and bonuses. However, due to the loss of exclusivity rights and a strategic shift, the sales representative workforce has been reduced, leaving only logistics specialists and managers in Europe. The business's financial success is based on the global sales of the original drug Vascepa for the prevention of myocardial infarctions.

amarincorp.com (AMRN): Price to Earnings Ratio from 07/04/2022 to 11/16/2026

Analytical breakdowns for Amarin Corporation plc

- price and consensus price forecast:
General company analysis:Amarin - AMRN
Manufactured product of amarincorp.com

The P/E ratio determines the investment payback period by comparing the current market price of a share with the issuer's net profit. The dynamics of the calculated price-to-earnings multiple allow for the real-time tracking of an asset's fundamental overvaluation. Low indicator values suggest undervaluation, though they may signal business stagnation. For Amarin Corporation plc (AMRN), this reflects the struggle for Vascepa's margins amid generic pressure and high litigation costs.